There are, however, some indirectly targeting antibody-based treatments to osteocyte-secreted molecules such as the recently FDA-approved sclerostin monoclonal antibody treatment for osteoporosis, promoting bone formation (Shakeri and Adanty 2020). This evidence concerns the gene SOST and osteoporosis.